| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1107741249 |
| P356 | DOI | 10.1186/S13643-018-0838-Y |
| P932 | PMC publication ID | 6195723 |
| P698 | PubMed publication ID | 30342540 |
| P50 | author | Hanne Christensen | Q89372166 |
| Christian Gluud | Q26265142 | ||
| Janus C Jakobsen | Q41279147 | ||
| P2093 | author name string | Thorsten Steiner | |
| Jan Purrucker | |||
| Christian Ovesen | |||
| P2860 | cites work | Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulants | Q53668632 |
| Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation | Q54033442 | ||
| Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy | Q71137317 | ||
| Hematoma growth in oral anticoagulant related intracerebral hemorrhage | Q81785203 | ||
| Use of PER977 to reverse the anticoagulant effect of edoxaban | Q85912324 | ||
| Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm | Q88792311 | ||
| Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016 | Q89098055 | ||
| Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients | Q24186523 | ||
| Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism | Q24187205 | ||
| Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation | Q24197843 | ||
| Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation | Q24200497 | ||
| The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials | Q24288961 | ||
| Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods | Q24288962 | ||
| Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 | ||
| The case of the misleading funnel plot | Q24676535 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab | Q26764882 | ||
| Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis | Q26783473 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 | ||
| Misleading funnel plot for detection of bias in meta-analysis | Q28144453 | ||
| Guidelines on oral anticoagulation with warfarin – fourth edition | Q28240666 | ||
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| Idarucizumab for Dabigatran Reversal | Q28263802 | ||
| Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses | Q29619185 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis | Q30234372 | ||
| Addressing missing outcome data in meta-analysis | Q30835835 | ||
| What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data | Q30926358 | ||
| Estimating required information size by quantifying diversity in random-effects model meta-analyses. | Q33521365 | ||
| Outcome of intracerebral hemorrhage associated with different oral anticoagulants | Q33617298 | ||
| Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes | Q33827840 | ||
| Toward evidence-based medical statistics. 2: The Bayes factor | Q33866194 | ||
| Prothrombin complex concentrates: an update | Q34003474 | ||
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34012421 | ||
| Predicting hematoma expansion after primary intracerebral hemorrhage | Q34040461 | ||
| Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation | Q34193483 | ||
| Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. | Q34501375 | ||
| Industry sponsorship and research outcome. | Q34551400 | ||
| Factor XI antisense oligonucleotide for prevention of venous thrombosis | Q35200286 | ||
| Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. | Q35650348 | ||
| Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants | Q35867449 | ||
| Trial Sequential Analysis in systematic reviews with meta-analysis | Q36298738 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type | Q36645135 | ||
| Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis | Q36776490 | ||
| Frequency of adverse events in patients with poor anticoagulation: a meta-analysis | Q36827674 | ||
| Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study | Q36981935 | ||
| Factor XIa inhibitors: A review of the patent literature | Q37087491 | ||
| Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses | Q37138228 | ||
| Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone | Q37201821 | ||
| Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials | Q37352419 | ||
| Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department | Q50489681 | ||
| Idarucizumab for Dabigatran Reversal - Full Cohort Analysis | Q50537918 | ||
| Introduction to Bayesian methods I: measuring the strength of evidence | Q51960307 | ||
| Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrat | Q53539960 | ||
| Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage | Q53541143 | ||
| Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. | Q38007409 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies | Q38044510 | ||
| Warfarin‐related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates | Q38061959 | ||
| Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. | Q38065635 | ||
| Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal | Q38127582 | ||
| Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. | Q38415781 | ||
| Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. | Q38446560 | ||
| Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin | Q38492053 | ||
| Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies | Q38533193 | ||
| Drug-eluting stents versus bare-metal stents for acute coronary syndrome. | Q38612419 | ||
| The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials | Q38627588 | ||
| Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. | Q38661819 | ||
| Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies | Q38894516 | ||
| Simple randomization did not protect against bias in smaller trials. | Q38930666 | ||
| An appraisal of meta-analysis guidelines: how do they relate to safety outcomes? | Q38950328 | ||
| POST-NOAC: Portuguese observational study of intracranial hemorrhage on non-vitamin K antagonist oral anticoagulants | Q39141348 | ||
| Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals | Q39440039 | ||
| Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study | Q39483529 | ||
| Outcomes in a Warfarin-Treated Population With Atrial Fibrillation | Q39581227 | ||
| Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial | Q39683385 | ||
| Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors | Q40528209 | ||
| Comment on: "Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews". | Q40546492 | ||
| Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors | Q41501792 | ||
| Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless | Q41758939 | ||
| Validity of meta-analysis in diabetes: we need to be aware of its limitations | Q41960606 | ||
| Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. | Q43503175 | ||
| Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? | Q43707230 | ||
| A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over‐anticoagulation with warfarin | Q43808475 | ||
| Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication | Q44314655 | ||
| Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study | Q44650294 | ||
| The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage | Q44865336 | ||
| Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | Q45173221 | ||
| When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts | Q47098319 | ||
| Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis | Q47142865 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials | Q47192223 | ||
| The ties that bind. | Q47589346 | ||
| Adverse Events Following International Normalized Ratio Reversal in Intracerebral Hemorrhage | Q47711718 | ||
| Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy | Q48682923 | ||
| Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. | Q48876772 | ||
| Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. | Q49155525 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulant | Q215118 |
| placebo | Q269829 | ||
| prothrombin complex concentrate | Q2044524 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 169 | |
| P577 | publication date | 2018-10-20 | |
| P1433 | published in | Systematic Reviews | Q18216009 |
| P1476 | title | Prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients associated with oral anticoagulant administration: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis | |
| P478 | volume | 7 |
Search more.